{"id":5869,"date":"2023-08-29T06:03:58","date_gmt":"2023-08-29T06:03:58","guid":{"rendered":"https:\/\/healthnewscentral.com\/?p=5869"},"modified":"2023-08-29T06:03:58","modified_gmt":"2023-08-29T06:03:58","slug":"fda-approves-very-first-fecal-transplant-pill-for-c-diff-recurrence-prevention","status":"publish","type":"post","link":"https:\/\/healthnewscentral.com\/fda-approves-very-first-fecal-transplant-pill-for-c-diff-recurrence-prevention\/","title":{"rendered":"FDA Approves Very First \u2018Fecal Transplant\u2019 Pill For C. Diff Recurrence Prevention"},"content":{"rendered":"
\"\"
Everyday Health<\/figcaption><\/figure>\n

On April 26, 2023, a groundbreaking milestone was achieved as the U.S. Food and Drug Administration (FDA)<\/a>\u00a0granted approval for the very first pill designed to replicate the effects of fecal transplants. Named \u201cVowst,\u201d this innovative treatment is crafted using healthy bacteria to combat the recurrence of Clostridium difficile (C. diff) infection<\/a> in adults who have undergone antibacterial therapy for recurrent C. diff infections.<\/p>\n

In the\u00a0FDA statement<\/a>, Peter Marks, MD, PhD<\/a>, the director of the FDA\u2019s Center for Biologics Evaluation and Research, said, \u201cToday\u2019s approval provides patients and healthcare providers a new way to help prevent recurrent\u00a0C. difficile<\/em>\u00a0infection.\u201d<\/p>\n

\u201cThe availability of a fecal microbiota product that can be taken orally is a significant step forward in advancing patient care and accessibility for individuals who have experienced this disease that can be potentially life-threatening,\u201d<\/strong><\/em> said Dr. Marks.<\/p>\n

    \n
  1. Diff Infection Causes Between 15K to 30K Deaths Annually<\/li>\n
  2. diff infection stands as one of the most prevalent healthcare-associated infections. It inflicts severe symptoms including persistent nausea, excruciating cramping, and debilitating diarrhea.Professor of pathology and infectious diseases at Stanford Medicine<\/a> in Palo Alto, California, Niaz Banaei, MD<\/a>, who was not involved in the development of Vowst, said, \u201cWhen the community of microorganisms inhabiting the gut and supporting our health is disturbed with antibiotics \u2014 usually prescribed for the treatment of unrelated medical issues \u2014\u00a0C. difficilecan expand in numbers and produce toxins that can damage the lining of the large gut.\u201d<\/strong><\/em><\/li>\n<\/ol>\n

    \u00a0If not managed properly, this condition can lead to dangerous complications, including gut inflammation and, in some traffic cases, death, explains Dr. Banaei. He goes on to say that approximately 15,000 to 30,000 people die of C. diff every year.<\/p>\n

    He also goes on to say that sadly, this disease process can recur due to particular members of the gut microbial community having vanished. Aside from taking antibiotics, other risk factors for recurrent CDI include the following:<\/p>\n